| State |
Study Site |
Indication |
Title |
Description |
Details |
| TX |
Texas Oncology-Baylor Charles Sammons Cancer Center |
Metastatic Melanoma |
An Open-Label, Multi-Center Phase II Study of Continuous Oral Dosing of R05185426 in Patients with Metastatic Melanoma, #NP22657 |
View |
| TX |
Texas Oncology-Baylor Charles Sammons Cancer Center |
Renal Cell Carcinoma |
Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma. |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Bladder Cancer |
Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma |
NCT00821327 |
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Brain Cancer |
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma (RTO |
NCT00884741 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
(CA180-158) Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women who have Hormone Receptor-positive Advanced Breast Cancer Previously Treated with an Aromatase Inhibitor |
NCT00754325 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
(CA180-185) Randomized Phase II Trial of Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic |
NCT00696072 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Breast Cancer |
(CRAD001W2301) A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-expressing Locally Advanced or Metastatic Breast Cancer
|
NCT01007942 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Lewisville,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
08007: Phase II Trial of Ixabepilone plus Carboplatin in Patients with Metastatic Breast Cancer |
NCT01075100 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Breast Cancer |
2010EAP: An Open-Label, Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer |
NCT01130259 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
3144A2-3004-WW: A Randomized Double Blind Placebo-Controlled Trial of Neratinib (HKI-272) Following Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
|
NCT00878709 |
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
3144A2-3005-WW: A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer |
NCT00915018 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East
|
Breast Cancer |
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab - CIRG (TRIO) 0 |
NCT00625898 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Kyle,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Breast Cancer |
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer (MBC)(ENZ-2208-03) |
NCT01036113 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
(NSABP B-46-I) |
NCT00887536 |
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Breast Cancer |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurently with Radiation and Radiation Alone for Women with Her2-Postive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy |
NCT00769379 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Breast Cancer |
A Randomized Phase III Study of Conventional Whole Breast
Irradiation (WBI) Versus Partial Breast Irradiation (PBI)
for Women with Stage 0, I, or II Breast Cancer (RTOG 0413) |
NCT00103181 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Southwest Fort Worth
|
Breast Cancer |
A Randomized, Phase III, Open-label Study of Lapatinib plus
Trastuzumab versus Trastuzumab as Continued HER2
Suppression Therapy after Completion of First- or Second-line
Trastuzumab plus Chemotherapy in Subjects with HER2-
positive Metastatic Breast |
NCT00968968 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Garland,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Tyler
|
Breast Cancer |
Amgen Protocol 20060359: A randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE) |
NCT01077154 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 status and Who Relapsed While Receivin |
NCT01068704 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Tyler
|
Breast Cancer |
An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 (T-DM1) Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Treated with the Equivalent T-DM1 Regimen in a Genentech and/or F. Hoffmann- |
NCT00781612 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Breast Cancer |
CRAD001-J2301: A randomized phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel, as first line therapy in women with HER2-positive locally advanced or metastatic breast cancer |
NCT00876395 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Sherman,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
EGF106708 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study.
A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive P |
NCT00490139 |
View |
TX
|
Texas Oncology-Memorial City,
Texas Oncology-Tyler
|
Breast Cancer |
Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers. (ET-B-027-06 )
|
NCT00580112 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Breast Cancer |
Protocol CTKI258A2202: A Multi-Center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-Amplified Metastatic HER2 Negative Breast Cancer |
NCT00958971 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Breast Cancer |
Triple Negative Breast Cancer Biomarker Study |
NCT01111175 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Colon Cancer |
(Panitumumab) 20060141: A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer with Wild-Type K |
NCT00418938 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Colon Cancer |
20060579 A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
|
NCT00813605 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Colon Cancer |
An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients with Locally Advanced or Metastatic Colorectal Cancer. E7820-701 |
NCT01133990 |
View |
TX
|
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Tyler
|
Colon Cancer |
PEAK - A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastati |
NCT00819780 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Endometrial Cancer |
E7080-G000-204: An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy |
NCT01111461 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Endometrial Cancer |
GOG 0249- A PHASE III TRIAL OF PELVIC RADIATION THERAPY VERSUS VAGINAL CUFF BRACHYTHERAPY FOLLOWED BY PACLITAXEL/CARBOPLATIN IN PATIENTS WITH HIGH-RISK, EARLY STAGE ENDOMETRIAL CANCER
|
NCT00807768 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Esophageal Cancer |
A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)
|
NCT00655876 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
GI Stromal Tumor (GIST) |
(CAMN107G2301): A randomized,open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). |
NCT00785785 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Head and Neck Cancer |
(I4E-MC-JXBD) A Randomized, Double-Blind, Phase 2 Safety Study of
Cetuximab, Using ImClone versus Boehringer Ingelheim
Manufacturing Processes, in Combination with Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients with |
NCT01081041 |
View |
TX
|
Texas Oncology-Medical City Dallas,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Tyler
|
Leukemia |
(CAMN107A2303) A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
|
NCT00471497 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin North,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Leukemia |
(OMB110911): A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia |
NCT00748189 |
View |
TX
|
Texas Oncology-Tyler
|
Leukemia |
APCYC-1102-CA: Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia |
NCT01105247 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Mesquite,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Sherman,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Leukemia |
The Chronic Lymphocytic Leukemia Disease Registry, CONNECT CLL |
NCT01081015 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Liver Cancer |
(CRAD001O2301): A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment– The EVOL |
NCT01035229 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Liver Cancer |
Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with SorafeNib (GIDEON) |
NCT00812175 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Sugar Land,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
(H3E-MC-JMIG): Phase 3 Study of Pemetrexed, Cisplatin,and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Adv |
NCT00686959 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Garland,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Lung Cancer |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) |
NCT00738387 |
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Lung Cancer |
A RANDOMIZED PHASE III COMPARISON OF STANDARD- DOSE (60 Gy) VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB (IND# 103444)IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER (RTO |
NCT00533949 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Rec |
NCT00858364 |
View |
TX
|
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Lung Cancer |
FORTIS-M: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens (LF-0207) |
NCT00707304 |
View |
TX
|
Texas Oncology-Sugar Land
|
Lung Cancer |
HYT105962: A randomized, phase III, open-label study of oral topotecan plus
whole-brain radiation therapy (WBRT) compared with WBRT
alone in patients with brain metastases from Non-Small Cell
Lung Cancer |
NCT00390806 |
View |
TX
|
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Southwest Fort Worth
|
Lung Cancer |
Protocol E7389-G000-205: A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer |
NCT01104155 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Lung Cancer |
Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or I |
NCT00762034 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center
|
Lung Cancer |
VGFT-ST-0708: A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma |
NCT00794417 |
View |
TX
|
Texas Oncology-Tyler
|
Lymphomas |
(C108083/3070): A Substudy to Assess the Effect of Treatment With Bendamustine in Combination with Rituximab on QT Interval in Patients with Advanced Indolent Non-Hodgkin's Lymphoma(NHL) or Mantle Cell Lymphoma(MCL) Within Study C18083/3064/NL/MN |
NCT01073163 |
View |
TX
|
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
(C18083/2048): An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL) |
NCT01108341 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
An open-label, single-arm phase II study of RAD001 in patients with mantle cell lymphoma who are refractory or intolerant to Velcade (bortezomib)
Protocol Number: CRAD001N2201
|
NCT00702052 |
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Lymphomas |
C18083/3064/NL/MN: An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, an |
NCT00877006 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
Protocol C05013 - An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma |
NCT00931918 |
View |
TX
|
Texas Oncology-Bedford,
Texas Oncology-Grapevine
|
Melanoma |
(E7080-G000-206): An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma |
NCT01136967 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Plano West,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Melanoma |
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma (111482) |
NCT00796445 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Tyler
|
Melanoma |
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors (E6201-A001-102) |
NCT00794781 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth
|
Melanoma |
A Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma (H8K-MC-JZAO) |
NCT01006252 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Melanoma |
E7080-702: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Dacarbazine versus Dacarbazine Alone as First Line Therapy in Patients with Stage IV Melanoma |
NCT01133977 |
View |
TX
|
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Lewisville,
Texas Oncology-Tyler
|
Myelodysplastic Syndrome |
A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO)
Protocol Number: CICL670A2302 |
NCT00940602 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris
|
Myelomas |
(CLBH589D2308): A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma |
NCT01023308 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Myelomas |
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib (Perifosine 339) |
NCT01002248 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Myelomas |
CONNECT (TM) MM - The Multiple Myeloma Disease Registry - Registry Protocol |
NCT01081028 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Tyler
|
Ovarian Cancer |
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer by CA125 (E7080-701 |
NCT01133756 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-South Austin,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Ovarian Cancer |
MORAb-003-004: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab
(MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relap |
NCT00849667 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-South Austin
|
Ovarian Cancer |
Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in
patients with advanced ovarian cancer |
NCT01015118 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Pancreatic Cancer |
A Phase 1b/2 Study Evaluating IPI-926 in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer (IPI-926-03) |
NCT01130142 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Prostate Cancer |
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815 |
NCT00936390 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Prostate Cancer |
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (Spport) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534) |
NCT00567580 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Kyle,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Prostate Cancer |
Protocol CC-5013-PC-002: A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer (CRPC) |
NCT00988208 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Solid Tumors |
A Phase 1, Multicenter, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor-alpha (PDGFR-alpha), |
NCT00816400 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer |
NCT00839332 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics of PG-11047 when Used in Individual Combinations with 1) Gemcitabine or 2) Docetaxel or 3) Be |
NCT00705874 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Solid Tumors |
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma (MEK111054)
|
NCT00687622 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
RDEA119-103: A Phase I/II Study of the Combination of RDEA119 and Sorafenib in Patients with Advanced Cancer |
NCT00785226 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Solid Tumors |
XL184-203: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors |
NCT00940225 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Supportive Care |
Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Rec |
NCT00858364 |
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Thromboses/Coagulation |
Protocol DU-176b-D-U305: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects with Symptomatic D |
NCT00986154 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Lewisville,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Round Rock,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Thymomas |
Phase II Study of Oral PHA-848125AC in Patients with Thymic Carcinoma Previously Treated with Chemotherapy (CDKO-125a-006) |
NCT01011439 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Grapevine,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Urothelial Cancer |
An Open-Label, Single-Arm, Phase II Trial of Intravenous BI 6727 in Patients with Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters after Failure of Prior Chemotherapy
Protocol #1230.2
|
NCT01023958 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Urothelial Cancer |
Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma |
NCT00821327 |
View |